Escolar Documentos
Profissional Documentos
Cultura Documentos
John N Clore MD
Virginia Commonwealth University
Richmond Virginia
T2DM Is Characterized by Insulin
Deficiency and Insulin Resistance
Overweight, Inactivity
Inherited/Acquired Factors (Inherited/Acquired)
Gluco-
lipotoxicity Glucose
Uptake
Production
of Glucose
in the Liver
Hyperglycemia
T2DM
? Insulin
HbA1c
overweight patients cohort, median values
9 Conventional Insulin Chlorpropamide Glibenclamide Metformin
8
HbA 1c (%)
6
0 0
2 4 6 8 10
Years from randomisation
ADA Recommendations
• HbA1c < 7.0%
• Preprandial plasma glucose
70-130 mg/dL (3.9-7.2 mM)
• Peak postprandial plasma glucose
< 180 mg/dL (<10 mM)
NHANES 2002
HbA1c
overweight patients cohort, median values
9 Conventional Insulin Chlorpropamide Glibenclamide Metformin
8
HbA 1c (%)
6
0 0
2 4 6 8 10
Years from randomisation
UKPDS-Any diabetes related endpoint
overweight
patients 0.6
Conventional (411)
Intensive (951)
Proportion of patients with events
Metformin (342)
0.4 M v C
p=0.0023
0.2
MvI
p=0.0034
0.0
0 3 6 9 12 15
Years from randomisation
Strategies for Management of T2DM
ADA/EASD Consensus Statement
Diagnosis
If A1C ≥ 7% If A1C ≥ 7%
80
-cell function (%)
60
40
20
0
-10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6
Time (years)
12/08/21 07:46 PM Cardiovascular 10
Adapted from UKPDS Group. Diabetes. 1995;44:1249-1258.
Kaplan-Meier Estimates of the Cumulative Incidence of Monotherapy Failure at 5 Years
• Lack of confidence
Insulin Requirements
80
60
40
20
0
<7.3 7.3–8.4 8.5–9.2 9.3–10.2 >10.2
A1C
Monnier L et al. Diabetes Care. 2003;26:881–885.
Insulin Preparations
Rapid-Acting
– Insulin lispro (analogue)
– Insulin aspart (analogue)*
– Insulin glulisine (analogue)
Short-Acting
– Regular (soluble)
Intermediate-Acting
– NPH (isophane)
Long-Acting
– Insulin glargine (analogue)
– Insulin detemir
A Basal Insulin Strategy
Continue oral agents
43 44
153
20 16 142 150
10 135 135
128 125
10 121 118 117 116
0 100
0* 2 4 6 8 10 12 14 16 18
Weeks in Study
Preliminary data.
*Week 0 based on a starting dose of 10 units.
Adapted from Rosenstock et al. ADA Annual Meeting. June 2001, Philadelphia, PA; Abst. 520-P.
Comparison of Glargine and Detemir